Medicinova Stock Price, News & Analysis

MediciNova, a biopharmaceutical company (NASDAQ:MNOV), announced that its abstract, titled “Improvement of Serum Lipid Panel by Tipelukast (MN-001) in Type 2 Diabetes and NAFLD Patients,” has been selected for presentation at the International Diabetes Federation (IDF) 2022 Congress on December 5-8, 2022. The presentation will be led by Chief Medical Officer, Kazuko Matsuda, MD. This study highlights MN-001's effectiveness in improving lipid profiles in NAFLD patients with Type 2 diabetes, showcasing significant results from a Phase 2 trial.

MediciNova, a biopharmaceutical company trading on NASDAQ under the symbol MNOV, announced a Notice of Allowance from the Korean Intellectual Property Office for a patent covering MN-001 (tipelukast) and its metabolite MN-002 for treating various fibrotic diseases. The patent is expected to expire in June 2035 and includes claims for multiple fibrotic conditions like Crohn's Disease and cystic fibrosis. The company believes this patent will enhance the potential value of MN-001, which has demonstrated anti-inflammatory and anti-fibrotic activities in preclinical models.

MediciNova, Inc. has initiated a Phase 2 clinical trial for MN-001 (tipelukast) targeting non-alcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus (T2DM), and hypertriglyceridemia. The trial includes approximately 40 patients aged 21 to 75, randomized to receive either MN-001 or a placebo for 24 weeks. Co-primary endpoints focus on changes in liver fat content and fasting serum triglycerides. Successful trial results may lead to pivotal Phase 3 trials aimed at supporting a New Drug Application (NDA) for MN-001.

MediciNova, a biopharmaceutical company listed on NASDAQ (MNOV), announced the start of a first-in-human clinical study for a new injectable formulation of MN-166 (ibudilast). This formulation aims to provide healthcare providers with more options for administering MN-166, especially in acute settings and precise injection locations. MN-166 has potential applications in treating various diseases, including ALS and multiple sclerosis. The company has a robust pipeline with several late-stage programs, indicating a strong commitment to advancing innovative therapies.

MediciNova announced a contract modification with BARDA to repurpose MN-166 (ibudilast) as a potential treatment for chlorine gas-induced lung damage, extending the project until March 2023. BARDA previously funded proof-of-concept studies for MN-166 as part of their ReDIRECT program, aiming to develop medical countermeasures against chemical threats. MN-166, a small molecule inhibiting inflammatory cytokines, is also in late-stage development for various neurodegenerative diseases and other conditions.

MediciNova, Inc. (MNOV) announced a research collaboration with Juntendo University to study the effects of MN-001 (tipelukast) on lipid metabolism and metabolic syndrome. Led by Dr. Takashi Mitsui, the research aims to deepen understanding of MN-001's mechanisms, which have shown benefits in reducing triglycerides and improving lipid profiles in previous clinical trials, particularly for patients with type 2 diabetes. MediciNova is focused on developing therapies for inflammatory and fibrotic diseases, with MN-001 being a key component in their clinical pipeline.

MediciNova announced positive results from its Phase 2 clinical trial of MN-166 (ibudilast) in COVID-19 patients at risk for acute respiratory distress syndrome (ARDS). The trial showed significant improvements in key endpoints: 71% of patients in the MN-166 group were free of respiratory failure at Day 7 compared to 35% in the placebo group (p=0.02). Additionally, 65% of MN-166 patients were discharged by Day 7 versus 29% in the placebo group (p=0.02). The results suggest MN-166’s potential efficacy in treating ARDS, addressing a significant medical need amidst high mortality rates in affected patients.

MediciNova has announced that executives Yuichi Iwaki and Geoffrey O'Brien will participate in a fireside chat at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 28, 2022, at 1:00 p.m. ET. This discussion will focus on the development of MN-166 (ibudilast), a compound targeting neurological conditions, including ALS and progressive MS. MN-166 is in late-stage clinical trials for various neurodegenerative diseases and is also being assessed for acute respiratory distress syndrome (ARDS) risk.

MediciNova, Inc. (NASDAQ: MNOV) announced the publication of research demonstrating that MN-166 (ibudilast) prevents metastasis in a uveal melanoma (UM) model. The study, published in Molecular Cancer Research, revealed that MN-166 significantly reduced UM cell migration and metastasis in mice, emphasizing its potential as an adjuvant therapy for UM patients. The research identified macrophage migration inhibitory factor (MIF) as a key target, suggesting that MIF inhibition through MN-166 could address critical needs in metastatic cancer treatment.